A Phase 2 interventional study of GDC-0853 in Rheumatoid Arthritis, sponsored by Genentech, Inc.. Completed at 104 sites in 10 countries. Open to participants aged 18 Years to 76 Years. Per ClinicalTrials.gov, last updated 2020-08-03.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Hoffmann-La Roche.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 28th largest by enrollment of the 141 interventional ones that give a count, is one of 8 that started in 2016, is one of 20 in phase 2, and was the 213th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Argentina, Brazil and 2 more countries
Ages 18+
Hoffmann-La Roche · Sites in United States, Argentina, Belgium and 9 more countries
Ages 18+
By country, each count listing its studies:
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 76 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
219 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 22 · Phase 3 85 · Phase 4 28
First in 2001; this study’s year is marked. 8 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 496 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 132 across the 141 interventional studies, 182 across the 78 observational. Of the 214 that completed or were terminated, 139 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
1 of the studies in Arthritis, Rheumatoid by Hoffmann-La Roche that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07137598Hoffmann-La RocheA Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) | 2027-04-17 |
Add it to your calendar (.ics) → With an account.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study to evaluate the long-term safety and efficacy of GDC-0853 in participants with moderate to severe active Rheumatoid Arthritis (RA) who have completed 12 weeks of study treatment in Study GA29350. Eligible participants from Study GA29350 who elect to participate will receive treatment with GDC-0853 twice daily (BID) in an open-label fashion for 52 weeks, followed by a safety follow-up period of 8 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received GDC-0853 orally twice daily (BID) for 52 weeks, after completing 12 weeks in Cohort 1 of Study GA29350. Cohort 1 participants in GA29350 were enrolled with moderate to severe active Rheumatoid Arthritis (RA) and an inadequate response to previous methotrexate (MTX) therapy and then randomized to 12 weeks of GDC-0853 (50 mg daily, 150 mg daily, or 200 mg BID), adalimumab, or placebo.
Drug: GDC-0853
Participants received GDC-0853 orally twice daily (BID) for 52 weeks, after completing 12 weeks in Cohort 2 of Study GA29350. Cohort 2 participants in GA29350 were enrolled with moderate to severe active Rheumatoid Arthritis (RA) and an inadequate response to one or two tumor necrosis factor (TNF) inhibitors and methotrexate (MTX) therapy, and then randomized to 12 weeks of GDC-0853 (200 mg BID) or placebo.
Drug: GDC-0853
GDC-0853 was administered orally at a dose of 200mg, as per the dosing schedules described above.
Also known as: RO7010939
Percentage of Participants With Adverse Events (AEs)
An Adverse Event (AE) was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events.
Time frame: Day 1 up until 8 weeks after the last dose of study drug (up to 1 year, 2 months)
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Week 52
ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
Time frame: Week 52
Percentage of Participants Achieving ACR50 Response up to Week 12
ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
Time frame: Weeks 4, 8 and 12
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response
ACR20 response is defined as a ≥ 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\]
Time frame: Weeks 4, 8, 12, 24, 36 and 52
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response
ACR70 response is defined as a ≥ 70% improvement (reduction) compared with Baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
Time frame: Weeks 4, 8, 12, 24, 36 and 52
Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 CRP)
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36 and 52
Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (4 Variables) (DAS28-4 CRP)
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36 and 52
Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 ESR)
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36 and 52
Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 ESR)
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36 and 52
Percentage of Participants With Remission Based on Disease Activity Score Based on 28-Joints Count (DAS28)
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control.
Time frame: Weeks 4, 8, 12, 24, 36 and 52
Percentage of Participants With Low Disease Activity (LDA) Based on DAS28
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. LDAS is defined as DAS28 ≤ 3.2
Time frame: Weeks 4, 8, 12, 24, 36 and 52
Percentage of Participants With ACR/EULAR Remission
Assessed according to the Boolean based definition (tender joint count =\<1, swollen joint count =\<1, C-reactive Protein (CRP) =\<1, and patient global assessment =\<1)
Time frame: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in Simplified Disease Activity Index (SDAI)
Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity
Time frame: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in Clinical Disease Activity Index (CDAI)
CDAI was derived as the sum of the following: tender joint count (TJC), swollen joint count (SJC), participant global assessment (PGA) of disease activity, and physician assessment of disease activity. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA and physician assessment of disease activity were scored 0-100 millimeters (mm) and rounded to the nearest centimeter (cm) on a visual analog scale (VAS), where higher scores indicate greater perceived disease activity. The total CDAI score range was 0-76, where higher scores indicate increased disease activity. Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest. Negative values indicate improvement/reduction in RA disease activity.
Time frame: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in Tender/Painful Joint Count Based on 68 Joints
Tender Joint Count: a total of 68 joints will be assessed for tenderness. Each joint is assessed for the presence/absence of tenderness. 68 joints are assessed for tenderness and joints are classified as tender/not tender giving a total possible tender joint count score of 0 to 68. A negative change from Baseline indicated improvement.
Time frame: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in Swollen Joint Count Based on 66 Joints
Swollen Joint Count: a total of 66 joints will be assessed for swelling. Each joint is assessed for the presence/absence of swelling. 66 joints were assessed for swelling and joints are classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66. A negative change from Baseline indicated improvement.
Time frame: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in Patient's Assessment of Arthritis Pain, Using Visual Analog Scale (VAS) Score
Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain
Time frame: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in Patient's Global Assessment of Arthritis, Using VAS Score
Participant-assessed arthritis pain was scored on a 100-mm VAS, where the distance from 0 mm represented the participant's self evaluation of arthritis pain (0 mm=none; 100 mm=very severe). Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest, where negative change indicated a decrease in participant-assessed arthritis pain.
Time frame: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in Physician's Global Assessment of Arthritis, Using VAS Score
Physician's assessment of participant's disease activity was scored on a 100-mm VAS, where the distance from 0 mm represented the physician's assessment of the participant's disease activity (0 mm=very good; 100 mm=very poor). Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest, where negative change from baseline indicated an improvement in physician-assessed disease activity.
Time frame: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in C-Reactive Protein (CRP) Levels
C-reactive protein is a biological marker of inflammation and is measured in milligrams per decilitre (mg/dL)
Time frame: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score
The Stanford Health Assessment Questionnaire disability index is a patient-reported outcome used to assess difficulty in performing activities of daily living. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. To respond to each question, a four-level response with higher scores showing larger functional limitations, was chosen. Scoring is as follows with respect to performance of participant's everyday activities: 0 (equals)=without difficulties; 1= with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. The composite HAQ-DI score is the mean of the eight domain scores and the score ranges from 0 (no functional impairment) to 3 (maximum functional impairment). A negative change from baseline indicates improvement.
Time frame: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Version 2.0 (V2) Scores for Physical and Mental Components
The 36-Item Short Form Health Survey (SF-36v2) is a questionnaire used to assess functional health and well-being and consists of eight domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. The SF-36v2 is summarized into Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. The PCS and MCS scores range from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.
Time frame: Weeks 12, 24 and 52
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score
The FACIT-Fatigue Scale consists of 13 items designed to measure the degree of fatigue experienced by the patient in the previous 7 days. For each question, there are five possible responses: 0 (not at all), 1 (a little bit), 2 (somewhat), 3 (quite a bit), 4 (very much). A total fatigue score is calculated by summing all items, and possible total scores range from 0 (maximum fatigue) to 52 (no fatigue). A positive change from baseline indicates an improvement in the patient's fatigue (less fatigue).
Time frame: Weeks 12, 24 and 52
Area Under the Concentration Time Curve (AUC) of GDC-0853 at Steady State (AUC,ss)
Population PK model estimated AUC of GDC-0853 at steady-state. AUC was measured in Nanograms (ng) per millilitre(mL)\*hour (hr).
Time frame: Pre-dose (0 hour) on Weeks 0 (Day 1), 4, 12, 24, 36, and 52/early termination
Minimum Plasma Concentration of GDC-0853 at Steady State (Ctrough,ss)
Population PK model estimated minimal plasma concentration (Ctrough) of GDC-0853 at steady-state (ss).
Time frame: Pre-dose (0 hour) on Weeks 0 (Day 1), 4, 12, 24, 36, and 52/early termination
Plasma Decay Half-Life of GDC-0853 at Steady State (t1/2,ss)
Population PK model estimated plasma decay half life of GDC-0853 at steady-state.
Time frame: Pre-dose (0 hour) on Weeks 0 (Day 1), 4, 12, 24, 36, and 52/early termination
Apparent Oral Clearance of GDC-0853 at Steady State (CL/F,ss)
Population PK model estimated apparent oral clearance of GDC-0853 at steady-state.
Time frame: Pre-dose (0 hour) on Weeks 0 (Day 1), 4, 12, 24, 36, and 52/early termination
The study was conducted at 138 centers in 19 countries.
| Milestone | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| Started | 410 | 86 |
| Completed | 351 | 72 |
| Not completed | 59 | 14 |
| Withdrew: Adverse event | 21 | 3 |
| Withdrew: Death | 3 | 0 |
| Withdrew: Lack of efficacy | 8 | 1 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Multiple reasons | 2 | 1 |
| Withdrew: Physician decision | 3 | 1 |
| Withdrew: Withdrawal by subject | 19 | 8 |
An Adverse Event (AE) was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events.
| Percentage | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| Percentage of Participants With Adverse Events (AEs) | 60.2 | 57.0 |
ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
| Percentage | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Week 52 | 57.1 (52.28 to 61.86) | 50.0 (39.43 to 60.57) |
ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
| Percentage | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| Week 4 | 37.1 (32.40 to 41.75) | 29.1 (19.47 to 38.67) |
| Week 8 | 42.4 (37.65 to 47.22) | 34.9 (24.81 to 44.96) |
| Week 12 | 45.6 (40.79 to 50.43) | 39.5 (29.20 to 49.87) |
ACR20 response is defined as a ≥ 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\]
| Percentage | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| Week 4 | 69.0 (64.55 to 73.50) | 58.1 (47.71 to 68.57) |
| Week 8 | 72.9 (68.63 to 77.23) | 68.6 (58.80 to 78.41) |
| Week 12 | 74.4 (70.17 to 78.62) | 73.3 (63.90 to 82.61) |
| Week 24 | 75.4 (71.20 to 79.54) | 72.1 (62.61 to 81.57) |
| Week 36 | 75.1 (70.94 to 79.31) | 72.1 (62.61 to 81.57) |
| Week 52 | 75.4 (71.20 to 79.54) | 68.6 (58.80 to 78.41) |
ACR70 response is defined as a ≥ 70% improvement (reduction) compared with Baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
| Percentage | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| Week 4 | 19.8 (15.90 to 23.61) | 12.8 (5.73 to 19.85) |
| Week 8 | 21.7 (17.72 to 25.70) | 17.4 (9.42 to 25.46) |
| Week 12 | 23.9 (19.77 to 28.03) | 19.8 (11.35 to 28.18) |
| Week 24 | 30.2 (25.80 to 34.69) | 20.9 (12.33 to 29.53) |
| Week 36 | 32.2 (27.67 to 36.72) | 25.6 (16.36 to 34.80) |
| Week 52 | 36.3 (31.69 to 41.00) | 27.9 (18.43 to 37.39) |
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.
| Score on a scale | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| Baseline | 5.49 ± 0.85 | 5.59 ± 0.90 |
| Week 4 | 3.64 ± 1.11 | 4.09 ± 1.19 |
| Week 8 | 3.48 ± 1.06 | 3.81 ± 1.15 |
| Week 12 | 3.37 ± 1.09 | 3.73 ± 1.11 |
| Week 24 | 3.16 ± 1.05 | 3.55 ± 1.18 |
| Week 36 | 3.05 ± 1.05 | 3.36 ± 1.06 |
| Week 52 | 2.90 ± 1.03 | 3.17 ± 1.28 |
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.
| Score on a scale | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| Baseline | 5.83 ± 0.88 | 5.95 ± 0.94 |
| Week 4 | 3.70 ± 1.19 | 4.22 ± 1.34 |
| Week 8 | 3.53 ± 1.13 | 3.92 ± 1.25 |
| Week 12 | 3.39 ± 1.14 | 3.81 ± 1.21 |
| Week 24 | 3.18 ± 1.13 | 3.64 ± 1.27 |
| Week 36 | 3.06 ± 1.14 | 3.44 ± 1.21 |
| Week 52 | 2.87 ± 1.09 | 3.22 ± 1.40 |
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.
| Score on a Scale | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| Baseline | 6.17 ± 0.79 | 6.38 ± 0.88 |
| Week 4 | 4.25 ± 1.16 | 4.80 ± 1.26 |
| Week 8 | 4.04 ± 1.14 | 4.51 ± 1.17 |
| Week 12 | 3.89 ± 1.16 | 4.40 ± 1.11 |
| Week 24 | 3.65 ± 1.08 | 4.15 ± 1.27 |
| Week 36 | 3.46 ± 1.15 | 3.96 ± 1.15 |
| Week 52 | 3.35 ± 1.14 | 3.74 ± 1.31 |
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.
| Score on a Scale | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| Baseline | 6.48 ± 0.85 | 6.71 ± 0.96 |
| Week 4 | 4.27 ± 1.25 | 4.89 ± 1.41 |
| Week 8 | 4.04 ± 1.23 | 4.58 ± 1.29 |
| Week 12 | 3.87 ± 1.23 | 4.44 ± 1.25 |
| Week 24 | 3.62 ± 1.16 | 4.20 ± 1.37 |
| Week 36 | 3.43 ± 1.24 | 3.99 ± 1.30 |
| Week 52 | 3.27 ± 1.20 | 3.74 ± 1.42 |
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control.
| Percentage of Participants | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| Week 4 | 8.8 | 7.0 |
| Week 8 | 10.7 | 8.1 |
| Week 12 | 13.9 | 8.1 |
| Week 24 | 17.8 | 14.0 |
| Week 36 | 22.4 | 11.6 |
| Week 52 | 25.6 | 23.3 |
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. LDAS is defined as DAS28 ≤ 3.2
| Percentage of Participants | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| Week 4 | 20.0 | 12.8 |
| Week 8 | 21.2 | 17.4 |
| Week 12 | 26.6 | 12.8 |
| Week 24 | 33.7 | 27.9 |
| Week 36 | 38.3 | 29.1 |
| Week 52 | 42.2 | 29.1 |
Assessed according to the Boolean based definition (tender joint count =\<1, swollen joint count =\<1, C-reactive Protein (CRP) =\<1, and patient global assessment =\<1)
| Percentage of Participants | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| Week 4 | 5.0 | 5.8 |
| Week 8 | 7.8 | 5.9 |
| Week 12 | 7.4 | 7.2 |
| Week 24 | 13.0 | 6.0 |
| Week 36 | 15.6 | 11.4 |
| Week 52 | 17.8 | 10.7 |
Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity
| Score on a Scale | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| Week 4 | -24.36 ± 13.58 | -21.00 ± 13.49 |
| Week 8 | -26.17 ± 13.58 | -24.06 ± 13.57 |
| Week 12 | -27.91 ± 12.89 | -25.21 ± 13.37 |
| Week 24 | -29.61 ± 13.14 | -26.45 ± 14.17 |
| Week 36 | -30.47 ± 13.72 | -28.22 ± 14.16 |
| Week 52 | -31.69 ± 13.12 | -29.68 ± 13.77 |
CDAI was derived as the sum of the following: tender joint count (TJC), swollen joint count (SJC), participant global assessment (PGA) of disease activity, and physician assessment of disease activity. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA and physician assessment of disease activity were scored 0-100 millimeters (mm) and rounded to the nearest centimeter (cm) on a visual analog scale (VAS), where higher scores indicate greater perceived disease activity. The total CDAI score range was 0-76, where higher scores indicate increased disease activity. Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest. Negative values indicate improvement/reduction in RA disease activity.
| Score on a Scale | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| Week 4 | -23.41 ± 13.11 | -19.81 ± 13.15 |
| Week 8 | -25.14 ± 13.06 | -22.48 ± 12.59 |
| Week 12 | -26.82 ± 12.31 | -23.82 ± 12.37 |
| Week 24 | -28.52 ± 12.52 | -25.09 ± 13.18 |
| Week 36 | -29.40 ± 12.99 | -26.66 ± 12.98 |
| Week 52 | -30.61 ± 12.43 | -27.43 ± 13.43 |
Tender Joint Count: a total of 68 joints will be assessed for tenderness. Each joint is assessed for the presence/absence of tenderness. 68 joints are assessed for tenderness and joints are classified as tender/not tender giving a total possible tender joint count score of 0 to 68. A negative change from Baseline indicated improvement.
| Score on a Scale | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| Week 4 | -15.02 ± 12.38 | -13.23 ± 12.27 |
| Week 8 | -16.11 ± 12.45 | -15.19 ± 12.59 |
| Week 12 | -16.55 ± 12.39 | -15.99 ± 12.03 |
| Week 24 | -17.96 ± 12.24 | -16.65 ± 11.35 |
| Week 36 | -18.48 ± 12.77 | -17.51 ± 11.60 |
| Week 52 | -18.70 ± 12.99 | -17.73 ± 11.88 |
Swollen Joint Count: a total of 66 joints will be assessed for swelling. Each joint is assessed for the presence/absence of swelling. 66 joints were assessed for swelling and joints are classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66. A negative change from Baseline indicated improvement.
| Score on a Scale | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| Week 4 | -10.20 ± 8.43 | -7.85 ± 6.71 |
| Week 8 | -10.95 ± 8.48 | -9.12 ± 6.65 |
| Week 12 | -11.40 ± 8.22 | -9.08 ± 6.84 |
| Week 24 | -11.93 ± 8.33 | -9.86 ± 6.61 |
| Week 36 | -12.15 ± 8.57 | -9.98 ± 6.96 |
| Week 52 | -12.17 ± 8.55 | -9.59 ± 8.78 |
Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain
| Score on a Scale | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| Week 4 | -30.62 ± 26.60 | -26.34 ± 25.98 |
| Week 8 | -32.57 ± 26.77 | -27.21 ± 23.36 |
| Week 12 | -35.68 ± 26.44 | -29.49 ± 26.70 |
| Week 24 | -37.19 ± 26.85 | -30.30 ± 26.42 |
| Week 36 | -39.50 ± 27.20 | -33.14 ± 27.22 |
| Week 52 | -42.40 ± 26.22 | -38.21 ± 26.37 |
Participant-assessed arthritis pain was scored on a 100-mm VAS, where the distance from 0 mm represented the participant's self evaluation of arthritis pain (0 mm=none; 100 mm=very severe). Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest, where negative change indicated a decrease in participant-assessed arthritis pain.
| Score on a Scale | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| Week 4 | -30.21 ± 27.47 | -26.03 ± 24.50 |
| Week 8 | -32.67 ± 26.85 | -28.79 ± 23.07 |
| Week 12 | -35.63 ± 26.19 | -31.16 ± 25.32 |
| Week 24 | -36.94 ± 27.23 | -31.76 ± 25.09 |
| Week 36 | -39.40 ± 26.77 | -33.73 ± 25.82 |
| Week 52 | -42.91 ± 25.90 | -36.58 ± 24.74 |
Physician's assessment of participant's disease activity was scored on a 100-mm VAS, where the distance from 0 mm represented the physician's assessment of the participant's disease activity (0 mm=very good; 100 mm=very poor). Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest, where negative change from baseline indicated an improvement in physician-assessed disease activity.
| Score on a Scale | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| Week 4 | -37.07 ± 20.75 | -30.65 ± 24.09 |
| Week 8 | -39.29 ± 20.30 | -35.32 ± 22.36 |
| Week 12 | -42.23 ± 20.20 | -37.37 ± 22.14 |
| Week 24 | -44.40 ± 20.94 | -41.11 ± 23.86 |
| Week 36 | -45.52 ± 20.76 | -43.13 ± 24.14 |
| Week 52 | -48.57 ± 19.99 | -44.81 ± 23.85 |
C-reactive protein is a biological marker of inflammation and is measured in milligrams per decilitre (mg/dL)
| (mg/dL) | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| Week 4 | -0.95 ± 2.18 | -1.09 ± 3.10 |
| Week 8 | -1.02 ± 2.41 | -1.58 ± 2.60 |
| Week 12 | -1.03 ± 2.21 | -1.40 ± 3.38 |
| Week 24 | -1.03 ± 2.48 | -1.46 ± 2.99 |
| Week 36 | -1.11 ± 2.44 | -1.56 ± 3.04 |
| Week 52 | -1.12 ± 2.55 | -1.81 ± 2.75 |
The Stanford Health Assessment Questionnaire disability index is a patient-reported outcome used to assess difficulty in performing activities of daily living. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. To respond to each question, a four-level response with higher scores showing larger functional limitations, was chosen. Scoring is as follows with respect to performance of participant's everyday activities: 0 (equals)=without difficulties; 1= with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. The composite HAQ-DI score is the mean of the eight domain scores and the score ranges from 0 (no functional impairment) to 3 (maximum functional impairment). A negative change from baseline indicates improvement.
| Score on a Scale | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| Week 4 | -0.70 ± 0.64 | -0.55 ± 0.56 |
| Week 8 | -0.77 ± 0.65 | -0.59 ± 0.62 |
| Week 12 | -0.80 ± 0.67 | -0.60 ± 0.59 |
| Week 24 | -0.83 ± 0.66 | -0.63 ± 0.58 |
| Week 36 | -0.89 ± 0.63 | -0.62 ± 0.66 |
| Week 52 | -0.98 ± 0.64 | -0.69 ± 0.62 |
The 36-Item Short Form Health Survey (SF-36v2) is a questionnaire used to assess functional health and well-being and consists of eight domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. The SF-36v2 is summarized into Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. The PCS and MCS scores range from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.
| Number on a Scale | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| Week 12 (Physical Component Score change) | 11.35 ± 9.13 | 8.22 ± 8.73 |
| Week 12 (Mental Component Score change) | 6.52 ± 12.98 | 4.74 ± 11.53 |
| Week 24 (Physical Component Score change) | 12.31 ± 9.12 | 8.28 ± 8.53 |
| Week 24 (Mental Component Score change) | 6.63 ± 13.23 | 6.08 ± 11.76 |
| Week 52 (Physical Component Score change) | 13.89 ± 9.32 | 10.42 ± 8.94 |
| Week 52 (Mental Component Score change) | 7.00 ± 13.81 | 6.77 ± 11.60 |
The FACIT-Fatigue Scale consists of 13 items designed to measure the degree of fatigue experienced by the patient in the previous 7 days. For each question, there are five possible responses: 0 (not at all), 1 (a little bit), 2 (somewhat), 3 (quite a bit), 4 (very much). A total fatigue score is calculated by summing all items, and possible total scores range from 0 (maximum fatigue) to 52 (no fatigue). A positive change from baseline indicates an improvement in the patient's fatigue (less fatigue).
| Score on a Scale | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| Week 12 | 11.44 ± 10.36 | 9.28 ± 8.51 |
| Week 24 | 11.74 ± 10.75 | 10.41 ± 8.51 |
| Week 52 | 12.87 ± 10.58 | 10.87 ± 9.25 |
Population PK model estimated AUC of GDC-0853 at steady-state. AUC was measured in Nanograms (ng) per millilitre(mL)\*hour (hr).
| Ng/mL*(hr) | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| Area Under the Concentration Time Curve (AUC) of GDC-0853 at Steady State (AUC,ss) | 13400 ± 6930 | 15600 ± 7850 |
Population PK model estimated minimal plasma concentration (Ctrough) of GDC-0853 at steady-state (ss).
| ng/mL | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| Minimum Plasma Concentration of GDC-0853 at Steady State (Ctrough,ss) | 387 ± 244 | 467 ± 285 |
Population PK model estimated plasma decay half life of GDC-0853 at steady-state.
| hr | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| Plasma Decay Half-Life of GDC-0853 at Steady State (t1/2,ss) | 7.94 ± 3.16 | 9.01 ± 4.9 |
Population PK model estimated apparent oral clearance of GDC-0853 at steady-state.
| L/hr | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| Apparent Oral Clearance of GDC-0853 at Steady State (CL/F,ss) | 39.5 ± 12.6 | 35.3 ± 10.3 |
Collected over Day 1 up until 8 weeks after the last dose of study drug (up to 1 year, 2 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GDC-0853 (200mg BID) Cohort 1 | 3/410 (0.7%) | 26/410 (6.3%) | 22/410 (5.4%) |
| GDC-0853 (200mg BID) Cohort 2 | 0/86 (0%) | 4/86 (4.7%) | 4/86 (4.7%) |
| Event | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| ATRIAL FIBRILLATIONCardiac disorders | 0/410 | 1/86 |
| PNEUMONIAInfections and infestations | 0/410 | 1/86 |
| HIP FRACTUREInjury, poisoning and procedural complications | 1/410 | 1/86 |
| BASAL CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/410 | 1/86 |
| ACUTE KIDNEY INJURYRenal and urinary disorders | 2/410 | 0/86 |
| VAGINAL HAEMORRHAGEReproductive system and breast disorders | 2/410 | 0/86 |
| IRON DEFICIENCY ANAEMIABlood and lymphatic system disorders | 1/410 | 0/86 |
| CARDIO-RESPIRATORY ARRESTCardiac disorders | 1/410 | 0/86 |
| DIARRHOEAGastrointestinal disorders | 1/410 | 0/86 |
| ENTEROCOLITISGastrointestinal disorders | 1/410 | 0/86 |
| Event | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 |
|---|---|---|
| URINARY TRACT INFECTIONInfections and infestations | 22/410 | 4/86 |
| Age, Continuous(Years) | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 | Total |
|---|---|---|---|
| Mean | 49.9 ± 11.7 | 53.5 ± 12.5 | 50.5 ± 11.9 |
| Sex: Female, Male(Participants) | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 | Total |
|---|---|---|---|
| Female | 334 | 64 | 398 |
| Male | 76 | 22 | 98 |
| Race/Ethnicity, Customized(Participants) | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 | Total |
|---|---|---|---|
| Hispanic or Latino | 136 | 30 | 166 |
| Not Hispanic or Latino | 267 | 56 | 323 |
| Not Stated | 2 | 0 | 2 |
| Unknown | 5 | 0 | 5 |
| Race/Ethnicity, Customized(Participants) | GDC-0853 (200mg BID) Cohort 1 | GDC-0853 (200mg BID) Cohort 2 | Total |
|---|---|---|---|
| American Indian or Alaska native | 27 | 11 | 38 |
| Asian | 1 | 0 | 1 |
| Black or African American | 7 | 2 | 9 |
| Multiple | 7 | 2 | 9 |
| Unknown | 3 | 0 | 3 |
| White | 365 | 71 | 436 |
Showing the first 100 of 104 sites across 10 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2016 to primary completion in Jul 2019, 31 months.
Results were first posted in Aug 2020, 1 year after primary completion.
Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 31 months is above that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fenebrutinib